Articles with public access mandates - Steven P. RoweLearn more
Not available anywhere: 13
Imaging of prostate-specific membrane antigen with small-molecule PET radiotracers: from the bench to advanced clinical applications
SP Rowe, MA Gorin, MG Pomper
Annual review of medicine 70 (1), 461-477, 2019
Mandates: US National Institutes of Health
Detection of 18F-FDG PET/CT occult lesions with 18F-DCFPyL PET/CT in a patient with metastatic renal cell carcinoma
SP Rowe, MA Gorin, HJ Hammers, MG Pomper, ME Allaf, MS Javadi
Clinical nuclear medicine 41 (1), 83-85, 2016
Mandates: US National Institutes of Health
Imaging of prostate-specific membrane antigen using [18F] DCFPyL
SP Rowe, MA Gorin, MG Pomper
PET clinics 12 (3), 289-296, 2017
Mandates: US National Institutes of Health
Clinical experience with 18F-labeled small molecule inhibitors of prostate-specific membrane antigen
SP Rowe, MA Gorin, RAS Fragomeni, A Drzezga, MG Pomper
PET clinics 12 (2), 235-241, 2017
Mandates: US National Institutes of Health
Flare on serial prostate-specific membrane antigen–targeted 18F-DCFPyL PET/CT examinations in castration-resistant prostate cancer: first observations
KA Zukotynski, J Valliant, F Bénard, SP Rowe, CK Kim, MG Pomper, ...
Clinical nuclear medicine 43 (3), 213-216, 2018
Mandates: US National Institutes of Health
Comparison of CNN-based Approaches for Detection of COVID-19 on Chest X-ray Images
KH Leung, SP Rowe, MG Pomper, Y Du
2020 IEEE Nuclear Science Symposium and Medical Imaging Conference (NSS/MIC …, 2020
Mandates: US National Institutes of Health
Renal oncocytoma: a challenging diagnosis
N Mirkheshti, N Farrukh, T Legesse, SP Rowe, J Gordetsky, A Hussain
Current opinion in oncology 34 (3), 243-252, 2022
Mandates: US National Institutes of Health, US Department of Veterans Affairs
Baseline PSMA‐PET/CT as a predictor of PSA persistence following radical prostatectomy in high‐risk nonmetastatic prostate cancer patients receiving neoadjuvant therapy
X Du, Y Dong, J Liu, Y Su, Y Zhu, J Pan, B Dong, R Chen, J Liu, Z Tong, ...
The Prostate 83 (11), 1112-1120, 2023
Mandates: National Natural Science Foundation of China
Partial response upon peptide receptor radionuclide therapy in a highly proliferative pancreatic neuroendocrine tumor
A Weich, SE Serfling, SP Rowe, LB Solnes, AK Buck, T Higuchi, ...
Clinical nuclear medicine 48 (6), 547-548, 2023
Mandates: German Research Foundation
Process validation, current good manufacturing practice production, dosimetry, and toxicity studies of the carbonic anhydrase IX imaging agent [111In]In‐XYIMSR …
RA De Silva, MA Gorin, RC Mease, I Minn, A Lisok, D Plyku, ...
Journal of Labelled Compounds and Radiopharmaceuticals 64 (6), 243-250, 2021
Mandates: US National Institutes of Health
Diagnostic performance of IQ· SPECT with high-speed scanning: A preliminary quality control study in obese patients
RA Werner, RB Martinez, C Marcus, MJ Kruse, S Sheikhbahaei, ...
Journal of Nuclear Cardiology 29 (6), 3443-3449, 2022
Mandates: German Research Foundation
18F-Fluciclovine–Avid Pulmonary Hamartoma
SC Baldeosingh, SP Rowe, SC Greco, CJ Paller, R Goel
Clinical nuclear medicine 46 (11), 919-921, 2021
Mandates: US National Institutes of Health
Assessment of anti-GAD65-associated cerebellar ataxia with 18F-FDG cerebellar uptake: ROC analysis
MS Sadaghiani, S Roman, Y Wang, SP Rowe, JP Leal, SD Newsome, ...
Annals of Nuclear Medicine 37 (9), 528-534, 2023
Mandates: US National Institutes of Health
Available somewhere: 161
Outcomes of observation vs stereotactic ablative radiation for oligometastatic prostate cancer: the ORIOLE phase 2 randomized clinical trial
R Phillips, WY Shi, M Deek, N Radwan, SJ Lim, ES Antonarakis, SP Rowe, ...
JAMA oncology 6 (5), 650-659, 2020
Mandates: US National Institutes of Health
Initial Evaluation of [18F]DCFPyL for Prostate-Specific Membrane Antigen (PSMA)-Targeted PET Imaging of Prostate Cancer
Z Szabo, E Mena, SP Rowe, D Plyku, R Nidal, MA Eisenberger, ...
Molecular imaging and biology 17, 565-574, 2015
Mandates: US National Institutes of Health
A Phase 2/3 Prospective Multicenter Study of the Diagnostic Accuracy of Prostate Specific Membrane Antigen PET/CT with 18F-DCFPyL in Prostate Cancer …
KJ Pienta, MA Gorin, SP Rowe, PR Carroll, F Pouliot, S Probst, ...
The Journal of urology 206 (1), 52-61, 2021
Mandates: US National Institutes of Health
Pearls and pitfalls in clinical interpretation of prostate-specific membrane antigen (PSMA)-targeted PET imaging
S Sheikhbahaei, A Afshar-Oromieh, M Eiber, LB Solnes, MS Javadi, ...
European journal of nuclear medicine and molecular imaging 44, 2117-2136, 2017
Mandates: US National Institutes of Health
PSMA-Based [18F]DCFPyL PET/CT Is Superior to Conventional Imaging for Lesion Detection in Patients with Metastatic Prostate Cancer
SP Rowe, KJ Macura, E Mena, AL Blackford, R Nadal, ES Antonarakis, ...
Molecular imaging and biology 18, 411-419, 2016
Mandates: US National Institutes of Health
Diagnostic Performance of 18F-DCFPyL-PET/CT in Men with Biochemically Recurrent Prostate Cancer: Results from the CONDOR Phase III, Multicenter Study
MJ Morris, SP Rowe, MA Gorin, L Saperstein, F Pouliot, D Josephson, ...
Clinical Cancer Research 27 (13), 3674-3682, 2021
Mandates: US National Institutes of Health
E-PSMA: the EANM standardized reporting guidelines v1. 0 for PSMA-PET
F Ceci, DE Oprea-Lager, L Emmett, JA Adam, J Bomanji, J Czernin, ...
European journal of nuclear medicine and molecular imaging 48, 1626-1638, 2021
Mandates: US National Institutes of Health
Publication and funding information is determined automatically by a computer program